| Original language | English |
|---|---|
| Pages (from-to) | 256-257 |
| Number of pages | 2 |
| Journal | The Lancet |
| Volume | 397 |
| Issue number | 10271 |
| DOIs |
|
| Publication status | Published (in print/issue) - 23 Jan 2021 |
Bibliographical note
Funding Information:CWlR declares grant funding from Science Foundation Ireland (12/YI/B2480), the Health Research Board (USIRL-2016-2), and the Irish Research Council (IRCLA/2017/234) in the area of type 2 diabetes. CWlR serves on advisory boards for Novo Nordisk, Herbalife, Boehringer Ingelheim, Johnson & Johnson, Keyron, AnaBio, and Sanofi, outside of the area of work commented on here. ADM declares no competing interests.
Funding
CWlR declares grant funding from Science Foundation Ireland (12/YI/B2480), the Health Research Board (USIRL-2016-2), and the Irish Research Council (IRCLA/2017/234) in the area of type 2 diabetes. CWlR serves on advisory boards for Novo Nordisk, Herbalife, Boehringer Ingelheim, Johnson & Johnson, Keyron, AnaBio, and Sanofi, outside of the area of work commented on here. ADM declares no competing interests.
Keywords
- Bariatric Surgery
- Diabetes Mellitus, Type 2/drug therapy
- Follow-Up Studies
- Glycated Hemoglobin A/analysis
- Humans